Logo

Inproteo Licenses Protein Purification Technique to ZymoGenetics

Jan 09, 2004

NEW YORK, Jan. 9 (GenomeWeb News) - Inproteo said today it has licensed a patent for a protein purification technique to ZymoGenetics.

 

ZymoGenetics' license to the so-called Smith patent, which protects the His tag fusion protein purification technique, covers all uses of the technology for the life of the patent.

 

Inproteo, formerly known as the Indiana Proteomics Consortium - a partnership between Indiana University, Purdue University, and Eli Lilly - recently obtained a license to the patent, U.S. Patent No. 4,569,794, from Eli Lilly. It holds the exclusive right to sublicense the patent and has already licensed it to a number of companies.

 

Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.